Isolated limb perfusion and infusion in the management of in-transit melanoma of the extremities: Modern data affecting practice

Jacob S. Ankeny, Jonathan S. Zager

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Melanoma is an aggressive cutaneous malignancy that can recur in the form of in-transit lesions. In-transit disease can present challenges for both physician and patient, particularly when unresectable and bulky. Multiple new therapeutic modalities have been introduced in recent time, but regional chemotherapy for extremity in-transit disease in theform of hyperthermic isolated limb perfusion and isolated limb infusion are useful tools in achieving disease response, improving survival in those that do not recur distantly, and helping to salvage limbs in cases where amputation is the only other treatment alternative. This chapter serves to cover the modern literature that guides current clinic practice using these modalities. While both are effective treatments, isolated limb infusion has gained momentum with increasing use due to its simplicity and similar disease response rates. With the introduction of new systemic agents, further research will need to look into the best ways that regional chemotherapy can be utilized within the scheme of a multimodality treatment plan for patients with in-transit extremity disease.

Original languageEnglish (US)
Title of host publicationCancer Regional Therapy
Subtitle of host publicationHAI, HIPEC, HILP, ILI, PIPAC and Beyond
PublisherSpringer International Publishing
Pages379-394
Number of pages16
ISBN (Electronic)9783030288914
ISBN (Print)9783030288907
DOIs
StatePublished - Jan 1 2019

Keywords

  • Extremity
  • HILP
  • ILI
  • In-transit disease
  • Melanoma
  • Metastatic melanoma
  • Regional chemotherapy
  • Unresectable

Fingerprint Dive into the research topics of 'Isolated limb perfusion and infusion in the management of in-transit melanoma of the extremities: Modern data affecting practice'. Together they form a unique fingerprint.

Cite this